number of weight loss drug prescriptions q3 2024 semaglutide tirzepatide New weight-loss drugs surge in popularity amid obesity surge in US, worldwide The FDA has approved the

March 20, 2026 / 14:31 IST Semaglutide Semaglutide patent expires in India on March 20, 2026

It is typically prescribed for patients with a BMI of 27 or higher , especially those with weight-related conditions such as high blood pressure or diabetes

By targeting all three pathways, these compounds may achieve greater metabolic effects than single or dual agonists

Loss continues at a rate of two to five pounds per month for most patients, though the pace gradually slows as you approach a metabolic floor

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, 11(4), 835844

An observational study conducted by Kings College London in 2022 elucidates that among participants who adhered stringently to the Wegovy administration protocol, a stark 80% experienced significantly enhanced weight loss compared to their less adherent counterparts